Jennison Associates LLC Buys New Shares in Hologic, Inc. (NASDAQ:HOLX)

Jennison Associates LLC bought a new stake in shares of Hologic, Inc. (NASDAQ:HOLX) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 420,981 shares of the medical equipment provider’s stock, valued at approximately $30,079,000.

Other large investors have also recently bought and sold shares of the company. Victory Capital Management Inc. raised its stake in shares of Hologic by 8.9% in the 3rd quarter. Victory Capital Management Inc. now owns 4,838,090 shares of the medical equipment provider’s stock valued at $335,763,000 after buying an additional 393,371 shares in the last quarter. TD Asset Management Inc raised its stake in shares of Hologic by 7.7% in the 3rd quarter. TD Asset Management Inc now owns 1,845,462 shares of the medical equipment provider’s stock valued at $128,075,000 after buying an additional 131,999 shares in the last quarter. Hsbc Holdings PLC raised its stake in shares of Hologic by 9.0% in the 3rd quarter. Hsbc Holdings PLC now owns 1,721,339 shares of the medical equipment provider’s stock valued at $119,472,000 after buying an additional 141,542 shares in the last quarter. DekaBank Deutsche Girozentrale raised its stake in shares of Hologic by 2.9% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 1,634,362 shares of the medical equipment provider’s stock valued at $115,586,000 after buying an additional 45,785 shares in the last quarter. Finally, Nordea Investment Management AB raised its stake in shares of Hologic by 4.5% in the 3rd quarter. Nordea Investment Management AB now owns 1,616,999 shares of the medical equipment provider’s stock valued at $113,077,000 after buying an additional 69,494 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on HOLX shares. Raymond James increased their price objective on shares of Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a research note on Friday, February 2nd. StockNews.com cut shares of Hologic from a “buy” rating to a “hold” rating in a research report on Friday, March 8th. Needham & Company LLC reiterated a “buy” rating and set a $90.00 target price on shares of Hologic in a research report on Wednesday, April 10th. UBS Group increased their target price on shares of Hologic from $78.00 to $79.00 and gave the stock a “neutral” rating in a research report on Friday, February 2nd. Finally, William Blair reissued an “outperform” rating on shares of Hologic in a report on Friday, February 2nd. Six investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $87.00.

Insider Buying and Selling

In other Hologic news, Director Charles J. Dockendorff sold 1,465 shares of the firm’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $76.21, for a total transaction of $111,647.65. Following the sale, the director now directly owns 1,572 shares in the company, valued at approximately $119,802.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CFO Karleen Marie Oberton sold 14,940 shares of the firm’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $75.00, for a total value of $1,120,500.00. Following the completion of the transaction, the chief financial officer now directly owns 103,916 shares of the company’s stock, valued at $7,793,700. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Charles J. Dockendorff sold 1,465 shares of the firm’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $76.21, for a total transaction of $111,647.65. Following the completion of the transaction, the director now directly owns 1,572 shares of the company’s stock, valued at $119,802.12. The disclosure for this sale can be found here. Insiders have sold 32,846 shares of company stock valued at $2,473,443 in the last 90 days. 1.75% of the stock is owned by insiders.

Hologic Stock Down 0.6 %

Shares of NASDAQ HOLX opened at $76.71 on Thursday. The firm has a market capitalization of $18.01 billion, a PE ratio of 36.36, a price-to-earnings-growth ratio of 2.61 and a beta of 1.00. The company has a current ratio of 3.89, a quick ratio of 3.18 and a debt-to-equity ratio of 0.55. Hologic, Inc. has a 1 year low of $64.02 and a 1 year high of $87.88. The firm’s 50-day moving average is $75.95 and its 200-day moving average is $72.72.

Hologic (NASDAQ:HOLX) last issued its earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.95 by $0.03. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $989.32 million. Hologic had a net margin of 12.98% and a return on equity of 18.91%. The company’s revenue for the quarter was down 5.7% on a year-over-year basis. During the same quarter last year, the firm earned $1.07 EPS. Equities analysts expect that Hologic, Inc. will post 4.01 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.